The aryl hydrocarbon receptor (AhR) is overexpressed in some patients with different tumor
types, and the receptor can be a negative or positive prognostic factor. There is also
evidence from both in vivo and in vitro cell culture models that the AhR can exhibit tumor-
specific pro-oncogenic and tumor suppressor-like functions and therefore can be treated
with AhR antagonists or agonists, respectively. Successful clinical applications of AhR
ligands will require the synthesis and development of selective AhR modulators (SAhRMs) …